ATTAIN-1 - Investigating Orforglipron for Obesity Management

Échec de l'ajout au panier.

Veuillez réessayer plus tard

Échec de l'ajout à la liste d'envies.

Veuillez réessayer plus tard

Échec de la suppression de la liste d’envies.

Veuillez réessayer plus tard

Échec du suivi du balado

Ne plus suivre le balado a échoué

ATTAIN-1 - Investigating Orforglipron for Obesity Management

Écouter gratuitement

Voir les détails du balado

À propos de cet audio

In this episode, Dr. Sean Wharton (University of Toronto and Wharton Medical Clinic, Canada) and Dr. Nasreen Alfaris (King Fahad Medical City, Riyadh, Saudi Arabia) join host Vivienne Parry to discuss the groundbreaking ATTAIN trial, presented at the EASD 2025 Annual Meeting in Vienna. The trial tested Orforglipron, the first oral small molecule GLP-1 receptor agonist, showing promising results in weight reduction and cardiometabolic improvements among people living with overweight or obesity. Beyond the data, the discussion explores what makes Orforglipron different, from its potential to expand access and affordability, to its implications for type 2 diabetes prevention. With obesity now the most common chronic disease worldwide, could this be a pivotal step toward truly scalable care?

Pas encore de commentaire